Targeted metabolomics and medication classification data from participants in the ADNI1 cohort

Lisa St John-Williams, Colette Blach, Jon B. Toledo, Daniel M. Rotroff, Sungeun Kim, Kristaps Klavins, Rebecca Baillie, Xianlin Han, Siamak Mahmoudiandehkordi, John Jack, Tyler J. Massaro, Joseph E. Lucas, Gregory Louie, Alison A. Motsinger-Reif, Shannon L. Risacher, Andrew Saykin, Gabi Kastenmüller, Matthias Arnold, Therese Koal, M. Arthur MoseleyLara M. Mangravite, Mette A. Peters, Jessica D. Tenenbaum, J. Will Thompson, Rima Kaddurah-Daouk

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disease presenting major health and economic challenges that continue to grow. Mechanisms of disease are poorly understood but significant data point to metabolic defects that might contribute to disease pathogenesis. The Alzheimer Disease Metabolomics Consortium (ADMC) in partnership with Alzheimer Disease Neuroimaging Initiative (ADNI) is creating a comprehensive biochemical database for AD. Using targeted and non-targeted metabolomics and lipidomics platforms we are mapping metabolic pathway and network failures across the trajectory of disease. In this report we present quantitative metabolomics data generated on serum from 199 control, 356 mild cognitive impairment and 175 AD subjects enrolled in ADNI1 using AbsoluteIDQ-p180 platform, along with the pipeline for data preprocessing and medication classification for confound correction. The dataset presented here is the first of eight metabolomics datasets being generated for broad biochemical investigation of the AD metabolome. We expect that these collective metabolomics datasets will provide valuable resources for researchers to identify novel molecular mechanisms contributing to AD pathogenesis and disease phenotypes.

Original languageEnglish (US)
Article number170140
JournalScientific data
Volume4
DOIs
StatePublished - Oct 17 2017

Fingerprint

Metabolomics
Alzheimer's Disease
Data Classification
dementia
medication
Disease
Neuroimaging
Data Preprocessing
Alzheimer's disease
Medication
Cohort
Phenotype
Neurodegenerative diseases
Pathway
Health
Continue
Defects
Economics
Trajectory
Resources

ASJC Scopus subject areas

  • Statistics and Probability
  • Information Systems
  • Education
  • Computer Science Applications
  • Statistics, Probability and Uncertainty
  • Library and Information Sciences

Cite this

St John-Williams, L., Blach, C., Toledo, J. B., Rotroff, D. M., Kim, S., Klavins, K., ... Kaddurah-Daouk, R. (2017). Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. Scientific data, 4, [170140]. https://doi.org/10.1038/sdata.2017.140

Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. / St John-Williams, Lisa; Blach, Colette; Toledo, Jon B.; Rotroff, Daniel M.; Kim, Sungeun; Klavins, Kristaps; Baillie, Rebecca; Han, Xianlin; Mahmoudiandehkordi, Siamak; Jack, John; Massaro, Tyler J.; Lucas, Joseph E.; Louie, Gregory; Motsinger-Reif, Alison A.; Risacher, Shannon L.; Saykin, Andrew; Kastenmüller, Gabi; Arnold, Matthias; Koal, Therese; Moseley, M. Arthur; Mangravite, Lara M.; Peters, Mette A.; Tenenbaum, Jessica D.; Thompson, J. Will; Kaddurah-Daouk, Rima.

In: Scientific data, Vol. 4, 170140, 17.10.2017.

Research output: Contribution to journalArticle

St John-Williams, L, Blach, C, Toledo, JB, Rotroff, DM, Kim, S, Klavins, K, Baillie, R, Han, X, Mahmoudiandehkordi, S, Jack, J, Massaro, TJ, Lucas, JE, Louie, G, Motsinger-Reif, AA, Risacher, SL, Saykin, A, Kastenmüller, G, Arnold, M, Koal, T, Moseley, MA, Mangravite, LM, Peters, MA, Tenenbaum, JD, Thompson, JW & Kaddurah-Daouk, R 2017, 'Targeted metabolomics and medication classification data from participants in the ADNI1 cohort', Scientific data, vol. 4, 170140. https://doi.org/10.1038/sdata.2017.140
St John-Williams L, Blach C, Toledo JB, Rotroff DM, Kim S, Klavins K et al. Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. Scientific data. 2017 Oct 17;4. 170140. https://doi.org/10.1038/sdata.2017.140
St John-Williams, Lisa ; Blach, Colette ; Toledo, Jon B. ; Rotroff, Daniel M. ; Kim, Sungeun ; Klavins, Kristaps ; Baillie, Rebecca ; Han, Xianlin ; Mahmoudiandehkordi, Siamak ; Jack, John ; Massaro, Tyler J. ; Lucas, Joseph E. ; Louie, Gregory ; Motsinger-Reif, Alison A. ; Risacher, Shannon L. ; Saykin, Andrew ; Kastenmüller, Gabi ; Arnold, Matthias ; Koal, Therese ; Moseley, M. Arthur ; Mangravite, Lara M. ; Peters, Mette A. ; Tenenbaum, Jessica D. ; Thompson, J. Will ; Kaddurah-Daouk, Rima. / Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. In: Scientific data. 2017 ; Vol. 4.
@article{420722b52cda42b2b809af21d46c145b,
title = "Targeted metabolomics and medication classification data from participants in the ADNI1 cohort",
abstract = "Alzheimer's disease (AD) is the most common neurodegenerative disease presenting major health and economic challenges that continue to grow. Mechanisms of disease are poorly understood but significant data point to metabolic defects that might contribute to disease pathogenesis. The Alzheimer Disease Metabolomics Consortium (ADMC) in partnership with Alzheimer Disease Neuroimaging Initiative (ADNI) is creating a comprehensive biochemical database for AD. Using targeted and non-targeted metabolomics and lipidomics platforms we are mapping metabolic pathway and network failures across the trajectory of disease. In this report we present quantitative metabolomics data generated on serum from 199 control, 356 mild cognitive impairment and 175 AD subjects enrolled in ADNI1 using AbsoluteIDQ-p180 platform, along with the pipeline for data preprocessing and medication classification for confound correction. The dataset presented here is the first of eight metabolomics datasets being generated for broad biochemical investigation of the AD metabolome. We expect that these collective metabolomics datasets will provide valuable resources for researchers to identify novel molecular mechanisms contributing to AD pathogenesis and disease phenotypes.",
author = "{St John-Williams}, Lisa and Colette Blach and Toledo, {Jon B.} and Rotroff, {Daniel M.} and Sungeun Kim and Kristaps Klavins and Rebecca Baillie and Xianlin Han and Siamak Mahmoudiandehkordi and John Jack and Massaro, {Tyler J.} and Lucas, {Joseph E.} and Gregory Louie and Motsinger-Reif, {Alison A.} and Risacher, {Shannon L.} and Andrew Saykin and Gabi Kastenm{\"u}ller and Matthias Arnold and Therese Koal and Moseley, {M. Arthur} and Mangravite, {Lara M.} and Peters, {Mette A.} and Tenenbaum, {Jessica D.} and Thompson, {J. Will} and Rima Kaddurah-Daouk",
year = "2017",
month = "10",
day = "17",
doi = "10.1038/sdata.2017.140",
language = "English (US)",
volume = "4",
journal = "Scientific data",
issn = "2052-4463",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Targeted metabolomics and medication classification data from participants in the ADNI1 cohort

AU - St John-Williams, Lisa

AU - Blach, Colette

AU - Toledo, Jon B.

AU - Rotroff, Daniel M.

AU - Kim, Sungeun

AU - Klavins, Kristaps

AU - Baillie, Rebecca

AU - Han, Xianlin

AU - Mahmoudiandehkordi, Siamak

AU - Jack, John

AU - Massaro, Tyler J.

AU - Lucas, Joseph E.

AU - Louie, Gregory

AU - Motsinger-Reif, Alison A.

AU - Risacher, Shannon L.

AU - Saykin, Andrew

AU - Kastenmüller, Gabi

AU - Arnold, Matthias

AU - Koal, Therese

AU - Moseley, M. Arthur

AU - Mangravite, Lara M.

AU - Peters, Mette A.

AU - Tenenbaum, Jessica D.

AU - Thompson, J. Will

AU - Kaddurah-Daouk, Rima

PY - 2017/10/17

Y1 - 2017/10/17

N2 - Alzheimer's disease (AD) is the most common neurodegenerative disease presenting major health and economic challenges that continue to grow. Mechanisms of disease are poorly understood but significant data point to metabolic defects that might contribute to disease pathogenesis. The Alzheimer Disease Metabolomics Consortium (ADMC) in partnership with Alzheimer Disease Neuroimaging Initiative (ADNI) is creating a comprehensive biochemical database for AD. Using targeted and non-targeted metabolomics and lipidomics platforms we are mapping metabolic pathway and network failures across the trajectory of disease. In this report we present quantitative metabolomics data generated on serum from 199 control, 356 mild cognitive impairment and 175 AD subjects enrolled in ADNI1 using AbsoluteIDQ-p180 platform, along with the pipeline for data preprocessing and medication classification for confound correction. The dataset presented here is the first of eight metabolomics datasets being generated for broad biochemical investigation of the AD metabolome. We expect that these collective metabolomics datasets will provide valuable resources for researchers to identify novel molecular mechanisms contributing to AD pathogenesis and disease phenotypes.

AB - Alzheimer's disease (AD) is the most common neurodegenerative disease presenting major health and economic challenges that continue to grow. Mechanisms of disease are poorly understood but significant data point to metabolic defects that might contribute to disease pathogenesis. The Alzheimer Disease Metabolomics Consortium (ADMC) in partnership with Alzheimer Disease Neuroimaging Initiative (ADNI) is creating a comprehensive biochemical database for AD. Using targeted and non-targeted metabolomics and lipidomics platforms we are mapping metabolic pathway and network failures across the trajectory of disease. In this report we present quantitative metabolomics data generated on serum from 199 control, 356 mild cognitive impairment and 175 AD subjects enrolled in ADNI1 using AbsoluteIDQ-p180 platform, along with the pipeline for data preprocessing and medication classification for confound correction. The dataset presented here is the first of eight metabolomics datasets being generated for broad biochemical investigation of the AD metabolome. We expect that these collective metabolomics datasets will provide valuable resources for researchers to identify novel molecular mechanisms contributing to AD pathogenesis and disease phenotypes.

UR - http://www.scopus.com/inward/record.url?scp=85031786081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031786081&partnerID=8YFLogxK

U2 - 10.1038/sdata.2017.140

DO - 10.1038/sdata.2017.140

M3 - Article

C2 - 29039849

AN - SCOPUS:85031786081

VL - 4

JO - Scientific data

JF - Scientific data

SN - 2052-4463

M1 - 170140

ER -